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The vitamin D receptor in cancer
James Thorne1* and Moray J. Campbell1,2
1Institute of Biomedical Research, Wolfson Drive, University of Birmingham Medical School, Edgbaston B15 2TT, UK
2Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo,
NY 14263, USA
Over the last 25 years roles have been established for vitamin D receptor (VDR) in influencing
cell proliferation and differentiation. For example, murine knock-out approaches have revealed
a role for the VDR in controlling mammary gland growth and function. These actions appear
widespread, as the enzymes responsible for 1a,25-dihydroxycholecalciferol generation and
degradation, and the VDR itself, are all functionally present in a wide range of epithelial and
haematopoietic cell types. These findings, combined with epidemiological and functional data,
support the concept that local, autocrine and paracrine VDR signalling exerts control over
cell-fate decisions in multiple cell types. Furthermore, the recent identification of bile acid
lithocholic acid as a VDR ligand underscores the environmental sensing role for the VDR.
In vitro and in vivo dissection of VDR signalling in cancers (e.g. breast, prostate and colon)
supports a role for targeting the VDR in either chemoprevention or chemotherapy settings.
As with other potential therapeutics, it has become clear that cancer cells display de novo
and acquired genetic and epigenetic mechanisms of resistance to these actions. Consequently,
a range of experimental and clinical options are being developed to bring about more targeted
actions, overcome resistance and enhance the efficacy of VDR-centred therapeutics.
Vitamin D receptor: 1a,25-Dihydroxycholecalciferol: Prostate cancer: Breast cancer
The cancer burden
The impact of cancer continues to be one of the greatest
burdens in the developed world and is also increasingly
impacting on the developing world. Approximately 1.5
million individuals will die from breast, colon or prostate
cancer this year, and the total number of deaths from can-
cer accounts for 13% of all deaths worldwide and for one
in every four deaths in the UK and USA(1). The impact is
also economic; $280 · 109 is spent annually worldwide on
the treatment of patients. Many cancers are however pre-
ventable, and through lifestyle choices such as smoking,
diet and exercise the worldwide incidence of cancer could
be cut by 40%(2,3).
Major risk factors for cancer
Diet
Recently, the appreciation of the impact of diet on cancer
has come to the fore, with a number of studies establishing
unequivocal relationships between diet and cancer initi-
ation and progression. Reflecting the accumulation of these
data, the WHO has now stated that diet forms the second-
most preventable cause of cancer (after smoking)(3). This
impact will rise further as a result of demographic factors,
and quite possibly because of changing dietary habits
worldwide, which will contribute further to the projected
increase in cancer incidence in developing nations. High-
profile malignancies such as breast, prostate, and colon
cancer typify this scenario, in which the aetiology of the
disease reflects the cumulative impact of dietary factors
over an individual’s lifetime(4–6). The relationship between
diet and disease is already exploited clinically, e.g. in the
Selenium and Vitamin E Cancer Prevention Trial to assess
the chemoprevention potential of vitamin E and Se in
prostate cancer(7–9).
Despite the importance and potential clinical benefit of
these relationships it remains unclear as to what is the
critical time-frame when dietary factors may be protective
against cancer development, e.g. during embryogenesis,
Abbreviations: 1a,25(OH)2D3, 1a,25-dihydroxycholecalciferol; 25OH-D, 25-hydroxycholecalciferol; RE, response elements; VDR, vitamin D receptor.
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childhood development or adult life. Resolving this issue
is, understandably, highly challenging. Considerable
resources were required to elucidate what is now estab-
lished as a clear causal relationship between cigarette
smoke and lung cancer. To address these issues the emer-
ging field of nutrigenomics aims to dissect the impact of
dietary factors on genomic regulation, and thereby phy-
siology and pathophysiology, utilizing a range of post-
genomic technologies(10).
The complex aetiology of cancer
The search for a genetic component(s) to many cancers in
this post-genomic era has failed to yield significant results
and only a few cancers appear to have a strong genetic
component. For example, mutations in the BRCA1 and
BRCA2 genes in breast cancer were identified in the 1990s
and typically show strong penetrance with a strong fami-
lial-linked risk, but these mutations contribute to <5% of
breast cancers(11,12). A more recent study implementing
genome-wide analyses has indicated five novel alleles that
are common in the population and increase the risk of
breast cancer, therefore suggesting a role for genetic
background in the susceptibility to breast cancer(13).
A contemporary view of cancer is that there are many low-
penetrance genetic factors that combine with environ-
mental insults over the lifetime of the individual to bring
about cancer. It is thought that in most cells, two insults
are required to lose control of the cell cycle control(14) and
between six and ten mutational events to develop into a
fully-mature cancer(15). The recent announcement of plans
to immunize girls between 12 and 13 years of age against
the sexually-transmitted human papillomavirus applies this
theory directly to prevent an essential environmental insult
required before a vital step in the transformation of normal
cells to cervical cancer can occur. This vaccination
programme is estimated to prevent approximately 70%
of cervical cancer cases in the UK(16). It is this complex
interaction between environmental and low-penetrance
genetic factors that means that age is the single biggest risk
factor for the development of cancer because, simply put,
there has been more time for environmental insults to
impact on precancerous cells.
The sporadic temporal acquisition of a cancer phenotype
is also compatible with models of disruption of the self-
renewal of epithelial tissues. It has become increasingly
clear that breast, colon and prostate tissues, in common
with other epithelial tissues and many other cell types in
the adult human subject, are self-renewing and contain
committed stem cell components(17–22). These stem cells
are slowly proliferating and are able to undergo asym-
metric divisions to give rise both to other stem cells and to
transiently-amplifying populations of progenitor cells. The
latter in turn give rise to the differentiated cell types that
typify the functions of these tissues and are subsequently
lost through programmed cell death processes and replaced
by newly-differentiated transiently-amplifying cells. The
mechanisms that control the intricate balance of these
processes of division, differentiation and programmed cell
death are the subjects of major investigations. These
studies have revealed common roles for Wnt and hedgehog
signalling and the actions of other signal transduction
processes that govern cell cycle progression, with gene
targets such as the cyclin-dependent kinase inhibitor
CDKN1A (p21(waf1/cip1)) emerging as points of criticality
upon which numerous signal pathways converge(18–21).
Stem cells of any tissue also have a high proliferative
capacity and are the ideal candidates for tumourigenesis
because they are programmed for self-renewal. It is likely
to take fewer disruptions to maintain this activation than
switching it on de novo in a more differentiated cell. Fur-
thermore, by self-renewing, stem cells are relatively long
lived compared with other cells within tissues. Although it
has become apparent that there are numerous mechanisms
in place in stem cells to ensure genomic integrity, the
longevity of these cells results in a greater likelihood of
genetic, cytogenetic or epigenetic disruptions accumulating
or being passed on to daughter progenitors(23).
Tissue self-renewal is controlled by intrinsic and
extrinsic cues, including a range of intrinsic, e.g. niche
signals, and extrinsic hormonal and dietary cues, which
appear to regulate many of the processes associated with
differentiation and programmed cell death(24,25). The pri-
mary genomic sensor for many dietary and environmental
(e.g. xenobiotic) factors is the nuclear receptor superfamily
of ligand-activated transcription factors, which bind steroid
hormones, vitamin micronutrients and macronutrients such
as fatty acids, lipids and bile acids(26–29).
The nuclear receptor superfamily
The nuclear receptor superfamily, the largest family of
transcription factors, is responsible for the sensing of hor-
monal, environmental and dietary-derived factors, and the
translation of these signals into appropriate transcriptional
responses(30–35). Often working co-operatively, nuclear
receptors converge on common gene targets to give tight
regulation of gene expression and repression. Thus, nuclear
receptors integrate dietary extracellular signals into cell-
fate decisions such as cell cycle control, self-renewal and
xenobiotic clearance.
Structure and function
A broad classification of the nuclear receptor superfamily
can be outlined according to ligand affinities. The first
group of receptors, exemplified by sex steroid and thyroid
hormone receptors, binds ligands with high affinity.
A number of nutrient-derived ligands are also bound with
high affinity by specific receptors. For example, 1a,25-
dihydroxycholecalciferol (1a,25(OH)2D3) and the retinoids
(all-trans- and 9-cis-retinoic acid) are bound by the vita-
min D receptor (VDR) and by the retinoic acid and retinoid
X receptors respectively. The second group of receptors,
e.g. the PPAR, liver X receptors and farnesoid X receptor,
bind with broader affinity more-abundant lipophilic com-
pounds such as macronutrients, PUFA and bile acids.
Finally, a group of orphan receptors exists, which either
has no functional ligand-binding domain or no ligands
have been identified as yet. By contrast, phylogenetic
classification has defined seven subfamilies, the VDR
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being in the group 1 subfamily, sharing homology with the
liver X receptors and farnesoid X receptor and more dis-
tantly the PPAR(36,37).
The nuclear receptors share a common architecture,
which includes defined regions for DNA recognition,
ligand binding and cofactor interactions. The DNA-binding
domain recognizes specific response elements (RE), which
were originally characterized in the enhancer–promoter
regions of target genes. More recently, such functionally-
responsive regions have been characterized in both intronic
and 30 regions and gene regulation is brought about
through the coordinated actions in multiple responsive
regions(18,38). Most receptors preferentially form homo- or
heterodimeric complexes; retinoid X receptor is a central
partner for VDR, PPAR, liver X receptors and farnesoid
X receptor. Thus, simple RE are formed by two recogni-
tion motives and their relative distance and orientation
contributes to receptor binding specificity, although more
recently larger, composite and integrated elements have
been identified, suggesting a more intricate control(23,39,40).
The vitamin D receptor
Metabolism of cholecalciferol and major cholecalciferol
functions
Systemic monitoring and regulation of serum Ca levels are
fundamentally important processes because of the vital
function that Ca plays in a wide range of cellular functions.
The VDR plays a well-established endocrine role in the
regulation of Ca homeostasis, in particular by regulating
Ca absorption in the gut and regulating bone minerali-
zation(41–43). In turn, 1a,25(OH)2D3 status is dependent on
cutaneous synthesis initiated by solar radiation and also
on dietary intake; a reduction in one or both sources leads
to vitamin D insufficiency. Interestingly, the contribution
from the UV-initiated cutaneous conversion of 7-dehydro-
cholesterol to vitamin D is the greater, contributing >90%
towards 1a,25(OH)2D3 synthesis in a vitamin D-sufficient
individual(44). The importance of the relationships between
solar exposure and the ability to capture UV-mediated
energy is underscored by the inverse correlation between
human skin pigmentation and latitude; i.e. the individual
capacity to generate 1a,25(OH)2D3 in response to solar
UV exposure is intimately associated with forebear envir-
onmental adaptation(44). The correct and sufficient level
of solar exposure and serum vitamin D are matters of
considerable debate. Current recommendations for daily
vitamin D intake are in the range of 10–20mg/d. More
recently, reassessment of the 1a,25(OH)2D3 impact on
the prevention of osteoporosis has suggested that the cor-
rect level may be as high as 50–75mg/d(45), which may
reflect more accurately ‘ancestral’ serum levels.
The importance of the relationship between UV expo-
sure and Ca homeostasis has been understood for >100
years and has driven the endocrine view of 1a,25(OH)2D3
signalling with spatially-distinct sites within the body of
incremental vitamin D activation. Thus, vitamin D pro-
duced in the skin is converted in the liver to 25-hydro-
xycholecalciferol, (25OH-D), and circulating levels of this
metabolite serve as a useful index of vitamin D status.
A further hydroxylation occurs in the kidney at the C-1
position by 25-hydroxyvitamin D-1a-hydroxylase
(encoded by CYP27b1) to produce the biologically-active
hormone 1a,25(OH)2D3(44). A second mitochondrial cyto-
chrome P450 enzyme, the 24-hydroxylase (encoded by
CYP24) enzyme, can utilize both 25OH-D and
1a,25(OH)2D3 as substrates and is the first step in the
inactivation pathway for these metabolites.
More recently, the expression of the 25OH-D activating
enzyme, CYP27b1, has been identified in keratinocytes and
a wide range of other cell types. In parallel, an autocrine–
paracrine role for the local synthesis and signalling of
1a,25(OH)2D3 has been uncovered(46–51). Thus, in multiple
target tissues 25OH-D may enter into an intracellular VDR
signalling axis that coordinates the local synthesis, meta-
bolism and signal transduction of 1a,25(OH)2D3. The
components of this axis have been shown to be regulated
dynamically, as CYP27b1 is repressed by 1a,25(OH)2D3
and correspondingly CYP24 is positively regulated by
1a,25(OH)2D3. Thus, elevated levels of 1a,25(OH)2D3
appear to block its synthesis and induce its own inacti-
vation(52) in a classical negative-feedback loop. The ability
of the VDR to play roles in both transactivation and trans-
repression reflects emerging themes for other nuclear recep-
tors, e.g. PPAR(53,54), and suggests a hitherto unsuspected
flexibility of the VDR to associate with a diverse array of
protein factors to adapt function(55,56). The biological
importance of these autocrine actions have been the subject
of intense investigation, and support the concept that the
VDR has two, perhaps distinct, broad biological roles,
i.e. the endocrine regulation of serum Ca and the auto-
crine–paracrine regulation of biological functions asso-
ciated with the regulation of cell proliferation and
differentiation and with the modulation of immune
responses.
Apo and Holo nuclear receptor states
A current challenge in nuclear receptor biology, and espe-
cially pertinent for the VDR, is to define mechanisms that
modulate and limit the transcriptional potential, and bring
about promoter targeting specificity. Expression, locali-
zation and isoform composition of co-repressor complexes
have emerged as important determinants of the spatio-
temporal equilibrium point between the antagonistic
actions of the apo and holo nuclear receptor complexes,
and consequently target gene promoter responsive-
ness(34,57–65).
Efforts to understand nuclear receptor function have at
their basis the antagonism between these apo and holo
nuclear receptor complexes, a direct effect of which is the
regulation of a diverse range of histone modifications.
Histone modifications at the level of meta-chromatin
architecture appear to form a stable and heritable ‘histone
code’, such as in X chromosome inactivation (for review,
see Turner(66)). The extent to which similar processes
operate to govern the activity of micro-chromatin contexts,
such as gene promoter regions, is an area of debate(67,68).
The apo and holo nuclear receptor complexes initiate speci-
fic and coordinated histone modifications(69,70) to govern
transcriptional responsiveness of the promoter. There is
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good evidence that specific histone modifications also
determine the assembly of transcription factors on the
promoter and control individual promoter transcriptional
responsiveness(71–73). It is less clear to what extent nuclear
receptors recognize basal histone modifications on target
gene promoters; functional studies of the SANT motif
contained in the co-repressor NCoR2/SMRT support this
latter idea(74). This area is complex and rapidly evolving
(for an excellent recent review, see Rosenfeld et al.(53)).
In the absence of ligand VDR–retinoid X receptor
dimers exist in an ‘apo’ state, as part of large complexes
(approximately 2.0 MDa)(75), associated with co-repressors
(e.g. NCoR2/SMRT) and bound to RE sequences. These
complexes actively recruit a range of enzymes that post-
translationally modify histone tails, e.g. histone deacetyl-
ases and methyltransferases, and thereby maintain a
locally condensed chromatin structure around RE sequen-
ces(29). Ligand binding induces a so-called holo state,
facilitating the association of the VDR–retinoid X receptor
dimer with co-activator complexes. A large number of
interacting co-activator proteins, which can be divided
into multiple families including the p160 family, the
non-p160 members and members of the large ‘bridging’
DRIP/TRAP/ARC complex, have been described that link
the receptor complex to the co-integrators CBP/p300 and
basal transcriptional machinery(26,45,76,77). These receptor–
co-activator complexes coordinate the activation of an
antagonistic battery of enzymes, such as histone acetyl-
transferases, and thereby induce the reorganization of local
chromatin regions at the RE of the target gene promoter.
The complex choreography of this event has recently
emerged and involves cyclical rounds of promoter-specific
complex assembly, gene transactivation, complex dis-
assembly and proteosome-mediated receptor degrad-
ation(26,45,78).
The expression, localization and isoforms of co-repres-
sor complexes have emerged as critical in determining the
spatio-temporal equilibrium between the antagonistic
actions of the apo and holo nuclear receptor complexes,
and thus determine target gene promoter responsiveness in
a range of physiological and pathological settings(79–81).
VDR and cancer
Evidence of vitamin D receptor involvement in cancer
In 1981 1a,25(OH)2D3 was shown to inhibit human mel-
anoma cell proliferation significantly in vitro at nanomolar
concentrations(82) and was subsequently found to induce
differentiation in cultured mouse and human myeloid
leukaemia cells(83,84). Following these studies anti-
proliferative effects have been demonstrated in a wide
variety of cancer cell lines, including those from the pros-
tate and breast(85–92). Thus, common models of VDR
responses include MCF-7 breast cancer cells, LNCaP
prostate cancer cells and CaCo2 colon cancer cells.
In order to identify critical target genes that mediate
these actions, comprehensive genome-wide in silico and
transcriptomic screens have analysed the anti-proliferative
VDR transcriptome and revealed broad consensus on cer-
tain targets, but has also highlighted variability(85,93–95).
This heterogeneity may in part reflect experimental condi-
tions, cell line differences and genuine tissue-specific dif-
ferences in cofactor expression that alter the magnitude
and extent of VDR transcriptional actions. The common
anti-proliferative VDR functions are associated with arrest
at G0/G1 of the cell cycle, coupled with up-regulation of
a number of cell cycle inhibitors including p21(waf1/cip1)
and p27(kip1). Promoter characterization studies have
demonstrated a series of vitamin D-responsive elements in
the promoter–enhancer region of CDKN1A, a primary
1a,25(OH)2D3-responding gene(96,97). By contrast,
p27(kip1) protein levels appear to be regulated by a range
of post-transcriptional mechanisms, such as enhanced
mRNA translation, and attenuating degradative mechan-
isms, often in a cell-type-specific manner(98–100). The up-
regulation of p21(waf1/cip1) and p27(kip1) principally mediate
G1 cell cycle arrest, but 1a,25(OH)2D3 has been shown to
mediate a G2/M cell cycle arrest in a number of cancer
cell lines via direct induction of GADD45a(94,101,102).
Again, this regulation appears to combine direct gene
transcription and a range of post-transcriptional mechan-
isms. These studies highlight the difficulty of establishing
strict transcriptional effects of the VDR, as a range of post-
transcriptional effects act in concert to regulate target
protein levels. Another VDR effect is associated with ele-
vated expression of a number of brush-border-associated
enzymes such as alkaline phosphatase, as well as inter-
mediate filaments, vinculin, ZO-1, ZO-2, desmosomes and
E-cadherin, which collectively enhance adhesion and sup-
press migration(103).
Another VDR action, notably in MCF-7 breast cancer
cells, is a profound and rapid induction of apoptosis, irre-
spective of p53 content, which may reflect the VDR role in
the involution of the post-lactating mammary gland. The
direct transcriptional targets that regulate these actions
remain elusive, although there is growing evidence of an
involvement of the BAX family of proteins(104,105). Induc-
tion of programmed cell death following 1a,25(OH)2D3
treatment is also associated with increased generation of
reactive oxygen species. 1a,25(OH)2D3 treatment up reg-
ulates VDUP1 encoding vitamin D up-regulated protein 1,
which binds to the disulfide-reducing protein thioredoxin
and inhibits its ability to neutralize reactive oxygen spe-
cies, thereby potentiating stress-induced apoptosis(106,107).
In other cells the apoptotic response is delayed and not so
pronounced, probably reflecting less-direct effects. Taken
together, these data suggest that the extent and timing of
apoptotic events depend on the integration of VDR sig-
nalling with other cell signalling systems.
Epidemiological evidence
Epidemiological studies by Garland and associates have
demonstrated that intensity of local sunlight is inversely
correlated with risk of certain cancers including breast,
prostatic and colo-rectal carcinoma(108–113). Supportively,
levels of 25OH-D, the major circulating metabolite of
vitamin D, are significantly lower in patients with breast
cancer than in age-matched controls(114). Furthermore,
there are reduced CYP27b1 mRNA and protein levels
in breast cancer cell lines and primary tumours(115).
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Comparative genome hybridization studies have found that
CYP24 is amplified in human breast cancer and CYP24
is associated with altered patterns of 1a,25(OH)2D3 meta-
bolism(51,116). Thus, over-expression of 24-hydroxylase
may further abrogate growth control mediated by
1a,25(OH)2D3, via target cell inactivation of the hormone.
It has therefore been proposed that breast cancer is asso-
ciated with low circulating concentrations of 25OH-D,
arising as a result of reduced exposure to sunlight, altered
dietary patterns and impaired generation of 1a,25(OH)2D3
within breast tissue(51,117–121).
Parallel epidemiological studies have also linked the
incidence of prostate cancer to vitamin D insufficiency as a
result of either diet or environment. In 1990 Schwartz and
colleagues suggested a role for vitamin D in decreasing
the risk for prostate cancer based on the observation that
mortality rates in the USA are inversely related to incident
solar radiation(112). Recently, a study of men in the San
Francisco Bay area has reported a reduced risk of advanced
prostate cancer associated with high sun exposure, and
similar relationships have been established in UK popu-
lations(110,122). As with breast cancer, the proposed mechan-
ism for the protective effects of sunlight on prostate risk
involves the local generation of 1a,25(OH)2D3 from cir-
culating 25OH-D in prostate epithelial cells. Cancerous
prostate cells express reduced 1a-hydroxylase activity.
Prediagnostic serum levels of 25OH-D have been assessed
in several prospective studies, with some reporting
increased risk among men with low circulating levels of
the vitamin D metabolite and a suggestion of an inverse
relationship with advanced disease(113,118–120).
As with breast and prostate cancer, some epidemiologi-
cal studies have noted that colon cancer risk and mortality
increase with increasing latitude; for example, adjusted
death rates from colon cancer in Caucasian males in the
USA are nearly three times higher in north eastern states
than in sunnier more southerly states(123).
In vivo studies
Vitamin D receptor-knock-out mice show increased
sensitivity to carcinogen challenge. Vdr-deficient mice
have become extremely useful tools in elucidating more
clearly the role for the VDR to act in a chemopreventive
manner. A series of mice have been generated in which
the VDR-ablated background has been crossed into differ-
ent tumour disposition phenotypes. Thus, crossing the
vdr-deficient and heterozygote mice with mouse mammary
tumour virus-neu transgenic mice has generated animals
that show an extent of VDR haplo-sufficiency. The mam-
mary tumour burden in the crossed mice is reduced by the
presence of one wild-type vdr allele, and further by two
wild-type vdr alleles(124). In addition, vdr- /- mice
demonstrate greater susceptibility to carcinogen challenge.
For example, treatment of these mice with dimethylben-
zanthracene induces more pre-neoplasic lesions in the
mammary glands than in wild-type mice(125).
Dietary-derived cholecalciferol inhibits tumour pro-
gression. A parallel and larger series of studies has
examined the ability of dietary or pharmacological addition
of vitamin D compounds either to prevent tumour
formation(126) or to inhibit growth of transplanted tumour
xenografts(127,128). Focusing on dietary regimens that
demonstrate tumour predisposition, long-term studies on
mice fed a Western-style diet (e.g. high fat and phosphate
and low vitamin D and Ca content) have shown increased
colonic epithelial cell hyperproliferation. Acute exposure
to these diets, e.g. over 12 weeks, has proved sufficient
to induce colon-crypt hyperplasia; effects that could be
ameliorated by the addition of Ca and vitamin D(129).
Another important model to test chemoprevention and
chemotherapy is the Apcmin mouse. APC is a key negative
regulator of b-catenin actions and is commonly disrupted
in human subjects developing colon cancer. The rate of
polyp formation in Apcmin mice is increased in mice fed a
Western diet compared with animals on standard chow.
Only moderate effects of 1a,25(OH)2D3 on polyp form-
ation are found in this model, associated with marked
hypercalcaemia. However, the effects are more pronounced
and significant when a potent analogue of 1a,25(OH)2D3 is
used, which also displays reduced toxicity(130).
The efficacy of 1a,25(OH)2D3 and its analogues has also
been extensively tested in carcinogen-induced models
in vivo, indicating a range of protective effects against
both tumour initiation, progression and invasion, and sup-
porting VDR chemoprevention and chemotherapy appli-
cations. In addition, immunodeficient mice injected with
human breast and other cancer cell lines show tumour
growth suppression and reduced angiogenesis in response
to 1a,25(OH)2D3(131,132).
Interaction between dietary components. A com-
plementary approach to these studies has examined the
capacity of 1a,25(OH)2D3 to interact with other dietary
components, which are known to be chemoprotective. One
such strategy has focused on the ability to enhance local
autocrine synthesis and signalling of 1a,25(OH)2D3. For
example, phyto-oestrogens, such as genestein or those in
soyabean meal, are known to be protective, and in vivo
feeding of these substances appears to increase CYP27B1
and reduce CYP24 expression in the mouse colon, resulting
in locally-elevated levels of 1a,25(OH)2D3(133). These
results would support the concept that Asian diets, rich in
phyto-oestrogens and vitamin D, may in part explain the
traditionally low rates of breast, prostate and colon cancer
in this region.
The vitamin D receptor in DNA damage and repair
The role of vitamin D in the skin is also suggestive of its
chemopreventive effects. UV light from sun exposure has
several effects in the skin; UVA light induces DNA
damage through increasing the level of reactive oxygen
species, but importantly UVB light also catalyses the con-
version of 7-dehydroxycholesterol to 25OH-D and induces
the expression of VDR.
Several lines of evidence suggest that vitamin D may
be protective of solar-induced DNA damage. The anti-
proliferative p21(waf1/cip1) and GADD45a genes are direct
targets of both VDR and the tumour suppressor p53.
In fact, at least two VDR and p53 RE that lie within
the promoter and enhancer regions of p21(waf1/cip1) are
so closely localized that functional interaction between
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promoter-bound VDR and p53 may be possible(97).
Cooperation between the VDR and p53 may therefore
be vital in mediating cell cycle arrest and the repair of
DNA within cells with solar and other types of DNA
damage.
In addition, antimicrobial and anti-inflammatory genes
are another subset of VDR targets that are induced by UV
radiation. Suppression of the adaptive inflammatory
response is thought to be protective for several reasons;
inflamed tissues contain more reactive oxygen species that
can damage DNA and prevent proper function of DNA
repair machinery, also the induction of cytokines and
growth factors associated with inflammation act to increase
the proliferative potential of the cells. NF-kB is a key
mediator of inflammation and the VDR attenuates this
process by negatively regulating NF-kB signalling(134).
This control by VDR is underscored by studies showing
that vdr- /- mice are more sensitive to chemicals that
induce inflammation than their wild-types counterparts(135).
The normally protective effect of inflammation that occurs
under other conditions is lost through this VDR-mediated
suppression but is compensated by the induction of a
cohort of antimicrobial and antifungal genes via the innate
immune response(136–138). The induction of antimicrobials
not only prevents infection in damaged tissue but can be
cytotoxic for cells with increased levels of anion phos-
pholipids within their membranes, a common feature of
transformed cells(139); experimental results are, however,
conflicting. Antimicrobials such as DCDMNQ show potent
anti-proliferative effects in prostate cancer cells lines such
as PC-3 and Du-145(140) and derivatives of 1,2,4-trizole are
cytotoxic against some colon and breast cancer cell
lines(141). However, the direct VDR target LL-37, also a
potent antimicrobial, appears to promote cellular pro-
liferation in HaCaT cells(142).
Combined, these epidemiological, in vivo and cell line
studies have supported the clinical evaluation of vitamin
D compounds in a range of cancer settings. Recent high-
dose and combination clinical trials targeting the VDR in
prostate cancer have proved encouraging and continue to
support therapeutic exploitation of this receptor(143–146).
The proposed chemoprotective role of the VDR in the skin
in terms of its interactions with p53, the suppression of
inflammation and promotion of innate immune responses
underscores the importance of vitamin D compounds in
the prevention of cancer as well as providing a novel
therapeutic target.
Mechanisms of disruption
A major limitation in the therapeutic exploitation of
1a,25(OH)2D3 in cancer therapies is the resistance of
cancer cells towards 1a,25(OH)2D3, as transformed cell
lines often display a spectrum of sensitivities including
complete insensitivity to 1a,25(OH)2D3, irrespective of
VDR expression. One research focus to overcome this
limitation has been to develop analogues of 1a,25(OH)2D3.
Multiple studies have demonstrated that these compounds
have some enhanced potency, but resistance remains an
issue. Further information about these analogues and their
uses can be found in the excellent review by Stein &
Wark(147). The VDR is neither commonly mutated nor is
there a clear relationship between VDR expression and
growth inhibition by 1a,25(OH)2D3(148). The molecular
mechanisms for 1a,25(OH)2D3 insensitivity in cancer are,
however, emerging.
Genetic resistance
The gene encoding the VDR protein is known to display
polymorphic variation. Thus, polymorphisms in the 30 and
50 regions of the gene have been described and variously
associated with risk of breast, prostate and colon cancer,
although the functional consequences remain to be estab-
lished clearly(149–155). For example, a start codon poly-
morphism in exon II at the 50 end of the gene, determined
using the fok-I restriction enzyme, results in a truncated
protein(156,157). At the 30 end of the gene three poly-
morphisms have been identified that do not lead to any
change in either the transcribed mRNA or the translated
protein. The first two sequences generate BsmI and ApaI
restriction sites and are intronic, lying between exons 8 and
9. The third polymorphism, which generates a TaqI
restriction site, lies in exon 9 and leads to a silent codon
change (from ATT to ATC), either of which insert an
isoleucine residue at position 352. These three poly-
morphisms are linked to a further gene variation, a vari-
able-length adenosine sequence within the 30 untranslated
region. The poly(A) sequence varies in length and can be
segregated into two groups: long sequences of eighteen to
twenty-four adenosines; short sequences(113,158–160). The
length of the poly(A) tail can determine mRNA stabi-
lity(161–163), so the polymorphisms resulting in long
poly(A) tails may increase the local levels of the VDR
protein.
Multiple studies have addressed the association between
VDR genotype and cancer risk and progression. In breast
cancer the ApaI polymorphism shows an association with
breast cancer risk, as indeed have the BsmI and the long-
sequence poly(A) variant. Similarly, the ApaI polymorph-
ism is associated with metastases to bone(164,165). The
functional consequences of the BsmI, ApaI and TaqI
polymorphisms are unclear but because of genetic linkage
may act as a marker for the poly(A) sequence within the 30
untranslated region, which in turn determine transcript
stability. Interestingly, combined polymorphisms and
serum 25OH-D levels have been shown to further com-
pound breast cancer risk and disease severity(166).
Earlier studies have suggested that polymorphisms in
the VDR gene might also be associated with risk of pros-
tate cancer. Ntais and co-workers have performed a meta-
analysis of fourteen published studies with four common
gene polymorphisms (Taq1, poly(A) repeat, Bsm1 and
Fok1) in individuals of European, Asian and African
descent. They have concluded that these polymorphisms
are unlikely to be major determinants of susceptibility
to prostate cancer on a wide population basis(167). Equally,
studies in colon cancer have yet to reveal conclusive rela-
tionships and may be dependent on the ethnicity of the
population studied.
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Epigenetic resistance
To date no cytogenetic abnormalities of the VDR have
been reported. Thus, exploration of epigenetic mechanisms
that disrupt VDR signalling is being undertaken by the
authors and by other groups. The lack of an anti-
proliferative response is reflected by a suppression of the
transcriptional responsiveness of anti-proliferative target
genes such as p21(waf/cipi1), p27(kip1), GADD45a and
BRCA1(87,102,168,169). Paradoxically, VDR transactivation is
sustained or even enhanced, as measured by induction of
the highly 1a,25(OH)2D3-inducible CYP24 gene(170,171).
Together these data suggest that the VDR transcriptome
is skewed in cancer cells to disfavour anti-proliferative
target genes, and that lack of functional VDR alone
cannot explain resistance. It has been proposed that
apparent 1a,25(OH)2D3 insensitivity is the result of
epigenetic events that skew the promoter responsiveness
to suppress responsiveness of specific target gene pro-
moters(172,173).
In support, frequently elevated co-repressor mRNA
expression has been found, most commonly involving
NCoR2/SMRT, in malignant prostate primary cultures and
cell lines, with reduced 1a,25(OH)2D3 anti-proliferative
response(81,87,169,174). These data indicate that the VDR: co-
repressor maybe critical in determining 1a,25(OH)2D3
responsiveness in cancer cells. It has been reasoned that
this molecular lesion could be targeted by co-treatment of
ligand (1a,25(OH)2D3) plus the histone deacetylase inhi-
bitors such as trichostatin A. These approaches restore
the 1a,25(OH)2D3 response of the androgen-independent
PC-3 cells to levels indistinguishable from those of control
normal prostate epithelial cells. This reversal of
1a,25(OH)2D3 insensitivity is associated with re-expres-
sion of gene targets associated with the control of pro-
liferation and induction of apoptosis, notably GADD45a.
A small interfering RNA approach towards NCoR2/SMRT
has demonstrated the important role this co-repressor
plays in regulating this response, with its repression
resulting in profound enhancement of the induction of
GADD45a in response to 1a,25(OH)2D3. These data sup-
port a central role for elevated NCoR2/SMRT levels to
suppress the induction of key target genes, resulting
in loss of sensitivity to the anti-proliferative action of
1a,25(OH)2D3(81,87,169).
In parallel studies a similar spectrum of reduced
1a,25(OH)2D3 responsiveness between non-malignant
breast epithelial cells and breast cancer cell lines has been
demonstrated(172,175). Again, this reduction is not deter-
mined entirely by a linear relationship between the levels
of 1a,25(OH)2D3 and VDR mRNA expression. Rather,
elevated co-repressor mRNA levels, notably NCoR1, in
oestrogen receptor a-negative breast cancer cell lines and
primary cultures are associated with 1a,25(OH)2D3 insen-
sitivity. Again targeting this molecular lesion through co-
treatments of 1a,25(OH)2D3 with histone deacetylases
inhibitors coordinately regulates VDR targets such as
p21(waf/cipi1) and GADD45a and restores anti-proliferative
responsiveness(172,175).
Together these data support the concept that altered
patterns of co-repressors inappropriately sustains histone
deacetylation around the vitamin D-responsive element of
target gene promoter–enhancer regions, and shifts the
dynamic equilibrium between apo and holo receptor con-
formations to favour transcriptional repression of key
target genes such as p21(waf1/cip1) or GADD45a. Thus,
VDR gene targets are less responsive in 1a,25(OH)2D3-
insensitive cancer cells compared with non-malignant
counterparts. Furthermore, targeting this molecular lesion
with co-treatments of cholecalciferol compounds plus his-
tone deacetylases inhibitors generates a temporal window
in which the equilibrium point between apo and holo
complexes is shifted to favour a more transcriptionally
permissive environment.
These findings complement a number of parallel studies
undertaken by other groups, which have established coop-
eration between 1a,25(OH)2D3 and butyrate compounds,
such as sodium butyrate(176–181). These compounds are
SCFA produced during fermentation by endogenous
intestinal bacteria and have the capacity to act as histone
deacetylases inhibitors. Stein and co-workers have identi-
fied the effects in colon cancer cells of 1a,25(OH)2D3+
sodium butyrate co-treatments to include the coordinate
regulation of the VDR itself. The authors’ studies, in the
time-frame studied (0–24 h), have shown no evidence for
changes in VDR mRNA levels on co-treatment with
1a,25(OH)2D3 plus trichostatin A. However, together these
studies underscore further the importance of the dietary-
derived milieu in the regulation of epithelial proliferation
and differentiation beyond sites of action in the gut.
Future therapeutic goals
These studies are a move towards chemoprevention appli-
cations and reflect the emerging appreciation of the impact
of diet on either the initiation or progression of cancer and
other aging syndromes. A simple preventative therapeutic
measure may involve the supplementation of staple foods
with vitamin D. Similar measures have been successfully
implemented in the USA through adding folic acid to bread
in response to the need for pregnant women to increase
their intake, and in the UK through increasing n-3 PUFA
levels in eggs by altering the composition of chicken feed.
For ‘next generation’ developments to occur, however,
it will be necessary to adopt a broader view of VDR sig-
nalling. Historically, researchers have studied the abilities
of single nuclear receptors such as the VDR to regulate a
discrete group of gene targets and influence cell function.
This approach has led to substantial knowledge concerning
many of these receptors individually. Cell and organism
function, however, depends on the dynamic interactions of
a collection of receptors through the networks that link
them and against the backdrop of intrinsic cellular pro-
grammes such as those governing development and dif-
ferentiation. The current lack of an integral view as to how
these interactions bring about function and dysfunction,
e.g. in the aging human individual, can be attributed to the
limitations of previously available techniques and tools to
undertake such studies. The implementation of post-geno-
mic techniques together with bioinformatics and systems
biology methodology is expected to generate an integral
view, thereby revealing and quantifying the mechanisms
Diet and cancer 121
P
ro
ce
ed
in
gs
o
f
th
e
N
u
tr
it
io
n
So
ci
et
y
by which cells, tissues and organisms interact with envir-
onmental factors such as diet(182,183).
Thus, it is probably naive to assume that the VDR alone
plays a key and dominant role in cell and tissue function
by acting singularly, but instead is intimately linked to the
actions of related nuclear receptors (e.g. PPAR, farnesoid
X receptor and liver X receptors) and cofactors. Equally,
the concept favoured is that the diverse signalling capacity,
which appears in the skin, is retained in most cell types and
reflects a combination of VDR function and its interactions
with intrinsic transcriptional programmes such as self-
renewal or geno-protection via p53.
The challenge is to model the spatio-temporal actions of
the nuclear receptor network and, in particular, the extent
to which the VDR exerts critical control over transcription
and translation. Such an understanding requires a clear
awareness of the chromatin architecture and context of
the promoter regions (e.g. histone modifications, DNA
methylation), genomic organization, gene regulation hier-
archies and 1a,25(OH)2D3-based metabolomic cascades,
all within the context of specific cell backgrounds. The
ultimate therapeutic goal will be to translate this under-
standing to strategies whereby only subsets of VDR actions
are targeted in discrete disease settings.
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